AT48641B - Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances. - Google Patents
Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.Info
- Publication number
- AT48641B AT48641B AT48641DA AT48641B AT 48641 B AT48641 B AT 48641B AT 48641D A AT48641D A AT 48641DA AT 48641 B AT48641 B AT 48641B
- Authority
- AT
- Austria
- Prior art keywords
- drug
- ineffective
- ergot
- freed
- production
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 5
- 229940079593 drug Drugs 0.000 title claims description 5
- 239000000126 substance Substances 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title claims description 3
- 238000000034 method Methods 0.000 title description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000207925 Leonurus Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung eines haltbaren, die therapeutisch wichtigen Bestandteile der Droge in ihren ursprünglichen Mengenverhältnissen enthaltenden, von unwirksamen und schädlichen Stoffen befreiten Präparates aus Mutterkorn.
Die grosse arzneiliche Bedeutung, die dem Mutterkorn zukommt, hat zu zahlreichen chemischen Untersuchungen geführt, deren Ergebnisse einander zum Teil widersprechen und noch keine vollständige Klarheit in dieses verwickelte Gebiet gebracht haben. Neuerdings haben'zwar Barger und Carr ("Journ. Chem. Soc."XCI, 1907, S. 337) und Barger und Dale ("Chem.
Ztbl."1907, I., S. 279) einige dieser Widersprtiche aufgeklärt und eine erhebliche Vereinfachung in der Benonnungsweiso und in der pharmako ! ogischon Be-
EMI1.1
der Pharmakopöen zu gross zu sein scheint, als dass sie auf der geringen Menge Ergotoxin, die in ihnen enthalten ist (von Barger und Carr rein dargestellt), beruhen könne ; es sei vielmehr wahrscheinlich, dass irgend ein anderes wirksames Prinzip darin vorhanden ist". Über die Natur dieses wirksamen Prinzipes ist man noch vollständig im Unklaren.
Es ist bekannt, dass das Mutterkorn und seine Extrakte sich bald zersetzen, so dass
EMI1.2
werden dürfen. Aber auch schon innerhalb dieses Zeitraumes nimmt ihre Wirkungsweise beträchtlich ah und wird ihr therapeutische Wirkung sicher.
Es wurde nun gefunden, dass ein gut haltbares Produkt von der vollen Wirkung der frischen Droge erhalten werden kann, wenn der wässrige Auszug des entfetteten Mutterkorens nach dem Neutralisieren und Einengen mit hochprozentigem A) kohol und Äther erschöpfend behando) t wird. Bei dieser Behandlung scheiden sich unwirksame Ballaststoffe (mit sehr geringen Mengen wirksamer Stoffe) aus, während der Hauptteil der wirksamen Stoffe in die alkoholisch-ätherische Losung übergeht. Aus dieser Lösung kann nun durch Einengen und Trocknen, vorteilhaft in der Luftleere, und nach Zumischen von Milchzucker oder anderen geeigneten Stoffen ein handliches Präparat gewonnen werden. das auf eine bestimmte Wirkungsweise eingestellt werden kann.
Beispiel : 10 kg gepulvertes und entfettetes Mutterkorn werden einige Male mit je 20 l Wasser warm ausgezogen, die Auszüge mit Alkali neutralisiert und in der Luft-
EMI1.3
dem Filtrat werden bei Luftleere die Lösungsmittel entfernt ; der Rückstand wird nach Zugabe von Milchzucker xur Trockne und in Pulverform gebracht.
EMI1.4
<Desc / Clms Page number 1>
Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances.
The great medicinal importance of ergot has led to numerous chemical investigations, the results of which contradict one another and have not yet brought complete clarity to this complex area. Recently, Barger and Carr ("Journ. Chem. Soc." XCI, 1907, p. 337) and Barger and Dale ("Chem.
Ztbl. "1907, I., p. 279) some of these contradictions cleared up and a considerable simplification in the designation and in the pharmako! Ogischon
EMI1.1
the pharmacopoeia seems to be too large to be based on the small amount of ergotoxine they contain (presented in pure form by Barger and Carr); it is rather probable that there is some other effective principle in it. "The nature of this effective principle is still completely in the dark.
It is known that ergot and its extracts soon decompose, so that
EMI1.2
may be. But even within this period of time, their mode of action increases considerably and their therapeutic effect is certain.
It has now been found that a well-preserved product can be obtained from the full effect of the fresh drug if the aqueous extract of the defatted motherwort is treated exhaustively after neutralization and concentration with high-percentage alcohol and ether. During this treatment, ineffective dietary fiber (with very small amounts of active substances) is eliminated, while the main part of the active substances passes into the alcoholic-ethereal solution. A handy preparation can now be obtained from this solution by concentration and drying, advantageously in a vacuum, and after adding lactose or other suitable substances. that can be adjusted to a specific mode of action.
Example: 10 kg of powdered and defatted ergot is drawn out a few times with 20 l of warm water, the extracts are neutralized with alkali and then left in the air.
EMI1.3
The solvents are removed from the filtrate in a vacuum; after adding lactose, the residue is brought to dryness and into powder form.
EMI1.4
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1907226468D DE226468C (en) | 1907-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT48641B true AT48641B (en) | 1911-06-26 |
Family
ID=5866033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT48641D AT48641B (en) | 1907-12-23 | 1908-11-09 | Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances. |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT48641B (en) |
-
1908
- 1908-11-09 AT AT48641D patent/AT48641B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2655844C3 (en) | Process for the production of anti-tumor substances | |
| AT391315B (en) | METHOD FOR PRODUCING ISOSILYBINE-FREE SILIBININE | |
| CH650404A5 (en) | ZEDRACHBORK EXTRACT WITH ANTINEOPLASTIC EFFECTIVENESS AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE1767098B1 (en) | Process for obtaining a vasoactive drug from the leaves of Ginkgo biloba | |
| DE3850262T2 (en) | METHOD FOR PRODUCING A PHYSIOLOGICALLY ACTIVE SUBSTANCE FROM SEEDSHELLS FROM FÖREE AND AN AGENT ACTIVE AGAINST INFECTIONS, MAINLY BASED ON THIS EXTRACT. | |
| AT48641B (en) | Process for the production of a durable preparation from ergot containing the therapeutically important components of the drug in their original proportions and freed from ineffective and harmful substances. | |
| EP0668768B1 (en) | Composition for controlling dermatomycoses and their agents, as well as transpiration and bodily odours | |
| DE2010788A1 (en) | Antigenic substances insoluble in water and process for their preparation | |
| DE1076888B (en) | Process for the production of active substances that promote breathing for therapeutic purposes | |
| DE3101001A1 (en) | METHOD FOR CONCENTRATING AND CLEANING THE ANTIHAEMOPHILIA FACTOR OR FACTOR VIII | |
| DE69009428T2 (en) | Process for producing a peach leaf extract and its use as a bath additive. | |
| DE226468C (en) | ||
| DE3000521A1 (en) | SUBSTANCE WITH INTERFERON INDUCING ACTIVITY AND METHOD FOR THEIR PRODUCTION | |
| DE950674C (en) | Process for obtaining active substances from aqueous extracts of Echinacea species | |
| DE657129C (en) | Process for the production of solutions or extracts from bacteria, pollen or other plant cells | |
| DE675605C (en) | Process for the separation and extraction of the valuable components of bee and snake venom | |
| DE820788C (en) | Process for the production of a yeast liver preparation | |
| DE1910715A1 (en) | Antimicrobial factors and their uses | |
| DE435530C (en) | Process for obtaining a therapeutically active substance | |
| DE711720C (en) | Process for the enrichment and recovery of a substance which increases the formation of leukocytes | |
| DE890562C (en) | Process for the production of a medicament for the treatment of abnormal cell growth | |
| AT287917B (en) | Process for the preparation of an extract containing an allergen | |
| DE432053C (en) | Process for the production of Allium preparations | |
| AT200257B (en) | ||
| AT300199B (en) | Process for the production of a water-soluble powder from mineral spring waters |